Dyslipidaemia (elevated triglycerides, low high-density lipoprotein-cholesterol [HDL-C] and an increase in small, dense low-density lipoprotein [LDL] particles) is an important contributor to the increased cardiovascular risk associated with type 2 diabetes. Lowering LDL-C levels with a statin is the main focus of lipid-modifying intervention. Fibrates are effective against all components of this atherogenic mixed dyslipidaemia. Adding a fibrate to primary statin therapy is a logical approach to achieving all lipid targets. Evidence from the Fenofibrate Invention and Event Lowering in Diabetes trial also shows that fenofibrate is a well-tolerated option with potential benefits on the progression of microvascular complications of type 2 diabetes. Thus fenofibrate-statin combination therapy may translate into greater reductions in vascular risk.fenofibrate, safety, type 2 diabetes.
Kannel WBLipids, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J1985;110:1100-07.
2.
Stamler J., Vaccaro O., Neaton JD et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care1993;16:434-44.
3.
Huxley R., Barzi F., Woodward M.Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ2006;332:73-8.
4.
Gu K., Cowie CC, Harris MIDiabetes and decline in heart disease mortality in US adults. JAMA1999;28:1291-7.
5.
Alberti Kgmm , Zimmet P., Shaw J.International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabetic Medicine2007;24:451-63.
6.
Blendea MC, McFarlane SI, Isenovic ER et al. Heart disease in diabetic patients. Curr Diabetes Rep2003;3:223-9.
7.
Unal B., Critchley JA, Capewell S.Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation2004 ;109:1101-07.
8.
Kendall DM, Bergenstal RMComprehensive management of patients with type 2 diabetes: establishing priorities of care. Am J Manag Care2001;7:S327-S43.
9.
Turner RC, Millns H., Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabete mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ1998;316:823-8.
10.
Ukpds.U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care1997 ;20:1683-7.
11.
Austin MA, Edwards KLSmall, dense low density lipoproteins, the insulin resistance syndrome and O non-insulin-dependent diabetes. Curr Opin Lipidol1996;7:167-71.
12.
St-Pierre AC , Cantin B., Dagenais GR et al. (Low-density lipoprotein sub-fractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol2005;25:553-9.
13.
Eckel RH, Kahn R., Robertson RM, Rizza RAPreventing cardiovascular disease and diabetes. A call to action from the American Diabetes Association and the American Heart Association. Circulation2006;113:2943-6.
14.
Jacobs MJ, Kleisli T., Pio JR et al. Prevalence and control of dyslipidaemia among persons with diabetes in the United States. Diabetes Res Clin Pract2005;70:263-9.
15.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood pressure in adults (Adult Treatment Panel III). JAMA2001;285:2486-97.
16.
Grundy SM, Gleeman JI, Mertz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation2004;110:227-39.
17.
Stone NJ, Bilek S., Rosenbaum S.Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol2005 ;96(suppl): 53E-59E.
18.
American Diabetes Association .Standards of medical care in diabetes-2006 . Diabetes Care2006;29(suppl 1):S4-S42.
19.
Smith SC, Allen J., Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation2006;113:2363-72.
20.
Ryden L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J2007;28:88-136.
21.
Baigent C., Keech A., Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366:1267-78.
22.
Costa J., Borges M., David C., Vaz Carneiro A.Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ2006;332:1115-24.
23.
Shepherd J. , Barter P., Carmena R. et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. The Treating to New Targets (TNT) study. Diabetes Care2006;29:1220-6.
24.
Ravnskov U. , Rosch PJ, Sutter MC, Houston MCShould we lower cholesterol as much as possible?BMJ2006 ;332:1330-2.
25.
Chapman MJFibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis2003 ;171:1-13.
26.
Fazio S., Linton MFThe role of fibrates in managing hyperlipidemia: mechanism of action and clinical efficacy. Curr Atherosclerosis Rep2004;6:148-57.
27.
Staels B., Dallongeville J., Auwerx J. et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism . Circulation1998;98:2088-93.
28.
Diabetes Atherosclerosis InterventionStudy investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes; the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet2001;357:905-10.
29.
Keech A., Simes RJ, Barter P. et al. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet2005;366:1849-61.
30.
Athyros VG, Papageorgiou AA, Athyrou VV et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care2002;25:1198-202.
31.
Derosa G., Cicero AE, Bertone G. et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther2004;26:1599-607.
32.
Durrington PN, Tuomilehto J., Hamann A. et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia . Diabetes Res Clin Pract2004; 64:137-51.
33.
Muhlestein JB, May HT, Jensen JR et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study . J Am Coll Cardiol2006;48:396-401.
34.
Feher MD, Caslake M., Foxton J. et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev1999;15:395-9.
35.
Vakkilainen J., Steiner G., Ansquer JC et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation2003;107:1733-7.
36.
Corti R., Osende J., Hutter R. et al. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis2007;190:106-13.
37.
Zambon A., Gervois P., Pauletto P. et al. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol2006;26:977-86.
38.
Barbier O., Pineda Torra I., Dugay Y. et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol2002;22:717-26.
39.
Staels B., Koenig W., Habib A. et al. Activation of human aortic smooth muscle cells is inhibited by PPAR-α but not by PPAR-γ activators. Nature1998;393:790-3.
40.
Marx M., Sukhova GK, Collins T. et al. PPAR-α activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation1999;99:3125-31.
41.
Rubins HB, Robins SJ, Collins D. et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med2002;162:2597-604.
42.
Koskinen P., Mantarri M., Manninen V. et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care1992;15:820-5.
43.
Tenkanen L., Mantarri M., Manninen V.Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation1995;92:1779-85.
44.
Robins SJ, Collins D., Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. JAMA2001;285:1585-91.
45.
Keech T., on behalf of the FIELD study investigators.Effects of long-term fenofibrate therapy on cardiovascular events among 9795 people with type 2 diabetes mellitus: the FIELD study, a randomised controlled trial. Atherosclerosis Suppl2006;7:342 [Abstract We-S15].
46.
Saha SA, Arora RR, Bahekar A. et al. Fibrates in the prevention of cardiovascular events in dyslipidemic patients: a meta-analysis of randomized placebo-controlled clinical trials . J Am Coll Cardiol2007;49(suppl A):abstract 1002-127.
47.
Keech A., Simes RJ, Barter P. et al. Correction to the FIELD study report. Lancet2006;368:1415.
48.
Ansquer JC, Foucher C., Rattier S. et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis2005;45;485-93.
49.
Wierzbicki AS, Mikhailidis DP, Wray R. et al. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin2003;19:155-68.
50.
Ballantyne CM, Corsini A., Davidson MH et al. Risk of myopathy with statin therapy in high-risk patients. Arch Intern Med2003 ;163:553-64.
51.
Rosenson RSCurrent overview of statin-induced myopathy . Am J Med2004;116:408-16.
52.
Alsheikh-Ali AA, Kuvin JT, Karas RHRisk of adverse events with fibrates. Am J Cardiol2004;94:935-8.
53.
Jones PH, Davidson MHReporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol2005 ;95:120-2.
54.
Prueksaritanont T., Subramanian R., Fang X. et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization . Drug Metab Dispos2002;30:505-12.
55.
Prueksaritanont T., Tang C., Qiu et al. Effects of fibrates on metabolism of statins in human hepatocytes . Drug Metab Dispos2002 ;30:1280-7.
56.
Corsini A., Bellosta S., Davidson MHPharmacokinetic interactions between statins and fibrates. Am J Cardiol2005;96(suppl):44K-49K.
57.
ACCORD Study Group, Buse JB, Bigger JT, Byington RPAction to Control Cardiovascular Risk in Diabetes trial: design and methods . Am J Cardiol2007;99:21i-33i.
